Sasinya N. Scott
YOU?
Author Swipe
View article: Gendered interpretations of the causes of breast cancer: a structured review of migrant studies
Gendered interpretations of the causes of breast cancer: a structured review of migrant studies Open
View article: Urinary Androgens Provide Additional Evidence Related to Metabolism and Are Correlated With Serum Androgens in Girls
Urinary Androgens Provide Additional Evidence Related to Metabolism and Are Correlated With Serum Androgens in Girls Open
Context Androgen levels are generally measured in serum samples, but urine may be a more feasible option, especially in children, as it is a noninvasive alternative. Objective To assess the correlations of 10 urinary androgen metabolites w…
View article: Supplementary Materials from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Materials from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 321KB, A detailed description of additional methods utilized (and associated references) for sequencing and analysis as well as an explanatory note regarding the TM pathway in yeast.
View article: Supplementary Materials from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Materials from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 321KB, A detailed description of additional methods utilized (and associated references) for sequencing and analysis as well as an explanatory note regarding the TM pathway in yeast.
View article: Data from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Data from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functi…
View article: Supplementary Tables 1 - 6 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Tables 1 - 6 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 2461KB, A complete listing of somatic mutations and rearrangements detected as well as targeted genes, sequences, MRN complex mutation frequency, and strains utilized.
View article: Supplementary Tables 1 - 6 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Tables 1 - 6 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 2461KB, A complete listing of somatic mutations and rearrangements detected as well as targeted genes, sequences, MRN complex mutation frequency, and strains utilized.
View article: Data from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Data from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
Metastatic solid tumors are almost invariably fatal. Patients with disseminated small-cell cancers have a particularly unfavorable prognosis, with most succumbing to their disease within two years. Here, we report on the genetic and functi…
View article: Supplementary Figures 1 - 10 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Figures 1 - 10 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 470KB, All supplementary figures including tumor histology, RAD50 immunohistochemistry, candidate mutations and their clonality, and supporting yeast and MEF experimental data.
View article: Supplementary Figures 1 - 10 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy
Supplementary Figures 1 - 10 from Synthetic Lethality in ATM-Deficient <i>RAD50</i>-Mutant Tumors Underlies Outlier Response to Cancer Therapy Open
PDF file - 470KB, All supplementary figures including tumor histology, RAD50 immunohistochemistry, candidate mutations and their clonality, and supporting yeast and MEF experimental data.
View article: Supplementary Figure 2 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 2 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 5171K, Schematic representation of gain or deletions across the set of genes on each chromosome in a tumor with MITF amplification. Each dot corresponds to an exon of a specific gene. Every gene expressed higher than 1.5 is cons…
View article: Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
XLSX file - 13K, Supplementary Table S3. Impact assay run statistics on all samples.
View article: Data from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Data from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated.Experimental Design: We conducted a …
View article: Data from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Data from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
Purpose: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated.Experimental Design: We conducted a …
View article: Supplementary Figure 2 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 2 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 5171K, Schematic representation of gain or deletions across the set of genes on each chromosome in a tumor with MITF amplification. Each dot corresponds to an exon of a specific gene. Every gene expressed higher than 1.5 is cons…
View article: Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
PDF file - 132K
View article: Supplementary Figure Legend from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure Legend from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 48K
View article: Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Table 3 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
XLSX file - 13K, Supplementary Table S3. Impact assay run statistics on all samples.
View article: Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
XLSX file - 910K, Supplementary Table S4. Impact assay exon coverage on all samples.
View article: Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
XLSX file - 910K, Supplementary Table S4. Impact assay exon coverage on all samples.
View article: Supplementary Figure 3 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 3 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 6545K, Detection of a K57N MEK1 mutation in DNA from formalin-fixed paraffin-embedded tumor and matched normal tissue from one patient. Multiple reads from tumor-derived DNA (panel on left) show a GC transversion in 21% of read…
View article: Supplementary Figure 1B from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 1B from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 2703K, Immunohistochemical (IHC) staining of low pAKT tumors
View article: Data from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Data from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
Purpose: Rapalogs are allosteric mTOR inhibitors and approved agents for advanced kidney cancer. Reports of clonal heterogeneity in this disease challenge the concept of targeted monotherapy, yet a small subset of patients derives e…
View article: Data from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Data from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
Purpose: Rapalogs are allosteric mTOR inhibitors and approved agents for advanced kidney cancer. Reports of clonal heterogeneity in this disease challenge the concept of targeted monotherapy, yet a small subset of patients derives e…
View article: Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Methods from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
PDF file - 132K
View article: Supplementary Figure 1B from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 1B from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 2703K, Immunohistochemical (IHC) staining of low pAKT tumors
View article: Supplementary Figure 1A from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 1A from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 2798K, Immunohistochemical (IHC) staining of high pAKT tumors
View article: Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
PDF file - 3248K, Supplementary Table S1. Histopathologic findings for multi-region analysis. Supplementary Table S2.IMPACT gene list and their respective chromosomal positions. Supplementary Table S5. WEC run statistics on patients #4 and…
View article: Supplementary Figure 3 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma
Supplementary Figure 3 from Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF<sup>V600E/K</sup>-Mutated Melanoma Open
PDF file - 6545K, Detection of a K57N MEK1 mutation in DNA from formalin-fixed paraffin-embedded tumor and matched normal tissue from one patient. Multiple reads from tumor-derived DNA (panel on left) show a GC transversion in 21% of read…
View article: Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Supplementary Figures 1 - 11, Tables 1 - 2 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy Open
PDF file - 3248K, Supplementary Table S1. Histopathologic findings for multi-region analysis. Supplementary Table S2.IMPACT gene list and their respective chromosomal positions. Supplementary Table S5. WEC run statistics on patients #4 and…